Candesartan for Migraine Prevention:

NCT04574713 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

450

Enrollment

OTHER

Sponsor class

Conditions

Migraine

Interventions

DRUG: Candesartan Oral Tablet 8 mg
DRUG: Candesartan Oral Tablet 16 mg
DRUG: Placebo oral tablet

Sponsor

St. Olavs Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]